TITLE

RoIe of cysteinyl leukotrienes in adenosine 5' -monophosphate induced bronchoconstriction in asthma

AUTHOR(S)
Rorke, S.; Jennison, S.; Jeffs, J. A.; Sampson, A. P.; Arshad, H.; Holgate, S. T.
PUB. DATE
April 2002
SOURCE
Thorax;Apr2002, Vol. 57 Issue 4, p323
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Adenosine induced bronchoconstriction in patients with asthma is thought to be mediated by the synthesis and release of autacoids from airway mast cells. In vitro, adenosine induced constriction of asthmatic bronchi is blocked by a combination of specific histamine and cysteinyl leukotriene receptor antagonists, but the relative contribution of these mediators in vivo is unclear. We hypothesised that adenosine induced bronchoconstriction in asthmatic patients may be blocked by pretreatment with the orally active selective cysteinyl leukotriene-1 (CysLT1) receptor antagonist, montelukast. Methods: In a randomised, double blind, crossover study, oral montelukast (10 mg) or placebo was administered once daily on two consecutive days to 1 8 patients with mild to moderate persistent atopic asthma. Incremental doses of adenosine 5'-monophosphate (AMP) from 0.39 to 400 mg/mI were inhaled by dosimeter and the dose producing a 20% fall in FEY1 (PC20AMP) after AMP inhalation was recorded. Leukotriene E4 (LTE4) urinary concentrations were measured by enzyme immunoassay 4 hours after AMP challenge. Results: Montelukast pretreatment provided highly significant protection against adenosine induced bronchoconstriction, with geometric mean PC20AMP values of 52.6 mg/mI (95% CI 35.2 to 78.7) after placebo and 123.9 mg/mI (95% Cl 83.0 to 185.0) after montelukast (p=0.006). The geometric mean of the montelukast/placebo PC20AMP ratio was 2.4 (95% Cl 1.3 to 4.2). Montelukast had no significant effect on 4 hour urinary excretion of LIE4 compared with placebo. Conclusions: Selective CysLT1 receptor antagonism with montelukast provides highly significant protection against AMP induced bronchoconstriction in patients with atopic asthma, implying that cysteinyl leukotrienes are generated from airway mast cells through preferential activation of their A28 receptors.
ACCESSION #
12948859

 

Related Articles

  • BTS guidelines for add-on therapy 'already out of date'. Dragon, Natalie // GP: General Practitioner;3/17/2003, p10 

    Reports that research on leukotriene receptor antagonists (LTRA) has challenged asthma guidelines recommended by the British Thorasic Society. Effectiveness of LTRA to control asthma; Contribution of David Price, researcher of the Clinical Observation of Montelukast as a Partner Agent for...

  • Breathe easier. Gordon, Mary Ebitt // Self;Apr97, Vol. 19 Issue 4, p95 

    Reports on the availability of leukotriene receptor antagonists or inhibitors, oral medications for asthma sufferers. Drugs in the category introduced in the market; Need for doctor's prescription on the kind of drug suited for severity of asthma.

  • Leukotriene receptor antagonists as add-on therapy for adults with asthma. Thomson, N.C.; Shepherd, M. // Thorax;Mar2003, Vol. 58 Issue 3, p190 

    Editorial. Examines the use of leukotriene receptor antagonists as add-on therapy for adults with moderate to severe asthma. Challenges in moderate and severe persistent asthma; Recommendations from asthma guidelines on the use of leukotriene receptor antagonists; Safety of the antagonists.

  • Focus on zafirlukast: A leukotriene receptor antagonist for the prophylaxis and chronic... Baldinger, Sandra L.; Shore, Eric T. // Formulary;Nov96, Vol. 31 Issue 11, p1029 

    Examines the use and effectiveness of zafirlukast, a potent and specific leukotriene receptor antagonist approved by the Food and Drug Administration (FDA) for the treatment of asthma in patients 12 years of age and older. Chemistry and pharmacology; Pharmacokinetics; Results of clinical trials...

  • Defining the role of antileukotriene agents in the management of asthma. Johnson, Margaret M. // Formulary;Jan2000, Vol. 35 Issue 1, p38 

    The newest class of asthma medications to be marketed in the United States are the antileukotriene agents (ALAs). They include one 5-lipoxygenase inhibitor, zileuton, and two leukotriene receptor antagonists, zafirlukast and montelukast. By inhibiting the formation of cysteinyl leukotrienes or...

  • Zafirlukast: A Review of its Pharmacology and Therapeutic Potential in the Management of Asthma. Adkins, J.C.; Brogden, R.N. // Drugs;Jan1998, Vol. 55 Issue 1, p121 

    Zafirlukast is a competitive and selective leukotriene receptor antagonist indicated for the prophylaxis and treatment of chronic asthma. The rationale for the development of leukotriene antagonists was based on in vitro and in vivo data demonstrating the extensive role of the cysteinyl...

  • Montelukast: A Viewpoint by Romain A. Pauwels. Pauwels, R.A. // Drugs;Aug1998, Vol. 56 Issue 2, p257 

    Offers views on the leukotriene antagonist montelukast used for treating asthma. Background on asthma; Effectiveness.

  • The Role of Mast Cells in the Pathophysiology of Asthma. Black, Judith // New England Journal of Medicine;5/30/2002, Vol. 346 Issue 22, p1742 

    Editorial. Focuses on the role of mast cells in the pathophysiology of asthma. Mentions an article by Brightling that studies the comparison of immunohistochemical analyses of biopsy specimens from patients with asthma, patients with eosinophilic bronchitis, and normal control subjects; Increase...

  • Asthma: mechanisms of disease.  // Thorax;Dec2004 Supplement, Vol. 59, p89 

    The article presents some papers related to mechanisms of asthma. Mast cells infiltrate the airway smooth muscle (ASM) of patients with asthma but not those with eosinophilic bronchitis, which is likely to be a key factor in the development of asthma. It is hypothesized that human lung mast...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics